» Articles » PMID: 36794375

Cost-effectiveness Analysis of Intradiscal Condoliase Injection Vs. Surgical or Conservative Treatment for Lumbar Disc Herniation

Overview
Journal J Med Econ
Date 2023 Feb 16
PMID 36794375
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: This study aimed to analyze the cost-effectiveness of intradiscal condoliase injection compared to surgical or conservative treatment for patients with lumbar disc herniation (LDH) who are refractory to conservative treatment.

Methods: We performed the following cost-effectiveness analyses: (I) condoliase followed by open surgery (for non-responders to condoliase) vs. open surgery from the beginning, (II) condoliase followed by endoscopic surgery (for non-responders to condoliase) vs. endoscopic surgery from the beginning, and (III) condoliase + conservative treatment vs. conservative treatment. In the first two comparisons with surgical treatments, we assumed that utilities were equal in both groups and estimated the tangible (treatment, adverse events, postoperative follow-up) and intangible (mental and physical burden, and productivity loss) costs based on the existing literature, the medical expense scoring table, and online questionnaire. In the last comparison without surgical treatment, we estimated the incremental cost-effectiveness.

Results: The average cost per patient of condoliase followed by open surgery (for non-responders to condoliase) was 701,643 yen, with a reduction of 663,369 in comparison to that of open surgery from the beginning (1,365,012 yen). The average cost per patient of condoliase followed by endoscopic surgery (for non-responders to condoliase) was 643,909 yen, with a reduction of 514,909 in comparison to that of endoscopic surgery from the beginning (1,158,817 yen). ICER was 1.58 million yen/QALY (ΔQALY = 0.119, 95% confidence interval: 0.059-0.180; Δcost = 188,809 yen at 2 years post-treatment).

Conclusions: Condoliase as a first line treatment option ahead of surgical treatment for LDH is superior, from a cost perspective, to surgical treatment from the beginning. Condoliase is also a cost-effective alternative to non-surgery conservative treatment.

Citing Articles

Clinical outcomes of unilateral biportal endoscopic discectomy (UBE) compared with conventional open lumbar discectomy with 3D microscope (OLDM) assisted.

Hao J, Chen R, Zheng J, Xu S, Xue H, Yao Y Medicine (Baltimore). 2025; 104(6):e41440.

PMID: 39928788 PMC: 11812994. DOI: 10.1097/MD.0000000000041440.


Immediate effectiveness of condoliase chemonucleolysis for lumbar disc herniation: a comparative study between patients with difficulty walking because of severe leg pain and those who can walk.

Hagizawa H, Kamatani T, Kitaguchi K, Kashii M Neurosurg Rev. 2025; 48(1):62.

PMID: 39825025 DOI: 10.1007/s10143-025-03196-8.


Early therapeutic efficacy of condoliase chemonucleolysis for lumbar disc herniation.

Kobayashi K, Sato K, Morita Y J Orthop Surg Res. 2024; 19(1):890.

PMID: 39734224 PMC: 11684254. DOI: 10.1186/s13018-024-05405-4.


Characteristics in patients with very early therapeutic response of condoliase chemonucleolysis for lumbar disc herniation.

Kamatani T, Kitaguchi K, Kashii M Neurosurg Rev. 2024; 47(1):422.

PMID: 39134904 DOI: 10.1007/s10143-024-02640-5.


Indication and Limitation of Intradiscal Condoliase Injection for Patients with Lumbar Disc Herniation: Literature Review and Meta-Analysis.

Nakajima H, Watanabe S, Honjoh K, Kubota A, Matsumine A Spine Surg Relat Res. 2024; 8(4):362-372.

PMID: 39131408 PMC: 11310530. DOI: 10.22603/ssrr.2023-0294.